| Compound | Survodutide |
|---|---|
| Category | GLP-1 / glucagon dual agonist |
| Class | GLP-1 and Incretin Therapies |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Survodutide is catalogued here as a glp-1 / glucagon dual agonist and graded at the "Clinical-stage" evidence tier. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
An investigational GLP-1/glucagon dual agonist (also known as BI 456906) under development for obesity, metabolic dysfunction-associated steatohepatitis, and type 2 diabetes.
Mechanism of Action
The molecule combines GLP-1 receptor agonism — the dominant driver of appetite and glycemic effects — with glucagon receptor agonism, which is studied for potential contributions to energy expenditure and hepatic fat reduction.
Research and Evidence
Phase 2 obesity results reported roughly 19% mean weight reduction at the highest tested dose over 46 weeks, and a phase 2 program in MASH has reported histological improvement. Phase 3 trials are ongoing.
Safety and Side Effects
Dose-related gastrointestinal effects have been the most prominent adverse events reported to date; the full safety profile is still being characterized in ongoing trials.
Frequently Asked Questions
What is the evidence tier of Survodutide?
Survodutide is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is Survodutide an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Survodutide?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered survodutide studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.